Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Sep;40(9):2232–2235. doi: 10.1128/aac.40.9.2232

In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria.

H M Wexler 1, E Molitoris 1, D Molitoris 1, S M Finegold 1
PMCID: PMC163509  PMID: 8878617

Abstract

The antimicrobial activity of trovafloxacin for 557 strains of anaerobic bacteria was determined by the National Committee for Clinical Laboratory Standards-approved Wadsworth agar dilution technique. The species tested included Bacteroides fragilis (n = 91), other members of the B. fragilis group (n = 130), Campylobacter gracilis (n = 15), other Bacteroides spp. (n = 16), Prevotella spp. (n = 49), Porphyromonas spp. (n = 15), Fusobacterium spp. (n = 62), Bilophila wadsworthia (n = 24), Sutterella wadsworthensis (n = 21), Clostridium spp. (n = 61), Peptostreptococcus spp. (n = 38), and gram-positive non-spore-forming rods (n = 35). Trovafloxacin inhibited all strains of B. fragilis at < or = 0.5 microgram/ml, 99% of other B. fragilis group species at < or = 2 micrograms/ml, and 96% of all anaerobes tested at < or = 2 micrograms/ml.

Full Text

The Full Text of this article is available as a PDF (208.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barry A. L., Fuchs P. C., Citron D. M., Allen S. D., Wexler H. M. Methods for testing the susceptibility of anaerobic bacteria to two fluoroquinolone compounds, PD 131628 and clinafloxacin. J Antimicrob Chemother. 1993 Jun;31(6):893–900. doi: 10.1093/jac/31.6.893. [DOI] [PubMed] [Google Scholar]
  2. Bauernfeind A. Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990. J Antimicrob Chemother. 1993 Apr;31(4):505–522. doi: 10.1093/jac/31.4.505. [DOI] [PubMed] [Google Scholar]
  3. Clarke A. M., Zemcov S. J. Comparative in vitro activity of lomefloxacin, a new difluoroquinolone. Eur J Clin Microbiol Infect Dis. 1989 Feb;8(2):164–168. doi: 10.1007/BF01963905. [DOI] [PubMed] [Google Scholar]
  4. Fernandes P. B., Shipkowitz N., Bower R. R., Jarvis K. P., Weisz J., Chu D. T. In-vitro and in-vivo potency of five new fluoroquinolones against anaerobic bacteria. J Antimicrob Chemother. 1986 Dec;18(6):693–701. doi: 10.1093/jac/18.6.693. [DOI] [PubMed] [Google Scholar]
  5. Fox A. R., Phillips I. The antibiotic sensitivity of the Bacteroides fragilis group in the United Kingdom. J Antimicrob Chemother. 1987 Oct;20(4):477–488. doi: 10.1093/jac/20.4.477. [DOI] [PubMed] [Google Scholar]
  6. Goldstein E. J., Citron D. M. Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria. Antimicrob Agents Chemother. 1992 May;36(5):1158–1162. doi: 10.1128/aac.36.5.1158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Goldstein E. J., Citron D. M. Comparative activity of the quinolones against anaerobic bacteria isolated at community hospitals. Antimicrob Agents Chemother. 1985 Apr;27(4):657–659. doi: 10.1128/aac.27.4.657. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Jones B. M., Geary I., Lee M. E., Duerden B. I. Activity of pefloxacin and thirteen other antimicrobial agents in vitro against isolates from hospital and genitourinary infections. J Antimicrob Chemother. 1986 Jun;17(6):739–746. doi: 10.1093/jac/17.6.739. [DOI] [PubMed] [Google Scholar]
  9. King A., Phillips I. The comparative in-vitro activity of eight newer quinolones and nalidixic acid. J Antimicrob Chemother. 1986 Nov;18 (Suppl 500):1–20. doi: 10.1093/jac/18.supplement_d.1. [DOI] [PubMed] [Google Scholar]
  10. Marshall S. A., Jones R. N. In vitro activity of DU-6859a, a new fluorocyclopropyl quinolone. Antimicrob Agents Chemother. 1993 Dec;37(12):2747–2753. doi: 10.1128/aac.37.12.2747. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Sato K., Hoshino K., Tanaka M., Hayakawa I., Osada Y. Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrob Agents Chemother. 1992 Jul;36(7):1491–1498. doi: 10.1128/aac.36.7.1491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Spangler S. K., Jacobs M. R., Appelbaum P. C. Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrob Agents Chemother. 1994 Oct;38(10):2471–2476. doi: 10.1128/aac.38.10.2471. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Sutter V. L., Kwok Y. Y., Bulkacz J. Comparative activity of ciprofloxacin against anaerobic bacteria. Antimicrob Agents Chemother. 1985 Mar;27(3):427–428. doi: 10.1128/aac.27.3.427. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Venezia R. A., Yocum D. M., Robbiano E. M., Echols R. M. Comparative in vitro activities of a new quinolone, WIN 57273, and piperacillin plus tazobactam against anaerobic bacteria. Antimicrob Agents Chemother. 1990 Sep;34(9):1858–1861. doi: 10.1128/aac.34.9.1858. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Watt B., Brown F. V. Is ciprofloxacin active against clinically important anaerobes? J Antimicrob Chemother. 1986 May;17(5):605–613. doi: 10.1093/jac/17.5.605. [DOI] [PubMed] [Google Scholar]
  16. Wexler H. M., Molitoris E., Finegold S. M. In vitro activities of three of the newer quinolones against anaerobic bacteria. Antimicrob Agents Chemother. 1992 Jan;36(1):239–243. doi: 10.1128/aac.36.1.239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Wexler H. M., Molitoris E., Reeves D., Finegold S. M. In vitro activity of DU-6859a against anaerobic bacteria. Antimicrob Agents Chemother. 1994 Oct;38(10):2504–2509. doi: 10.1128/aac.38.10.2504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Wexler H. M., Molitoris E., Reeves D., Finegold S. M. In-vitro activity of clinafloxacin (CI-960) and PD 131628-2 against anaerobic bacteria. J Antimicrob Chemother. 1994 Oct;34(4):579–584. doi: 10.1093/jac/34.4.579. [DOI] [PubMed] [Google Scholar]
  19. Wexler H. M., Reeves D., Summanen P. H., Molitoris E., McTeague M., Duncan J., Wilson K. H., Finegold S. M. Sutterella wadsworthensis gen. nov., sp. nov., bile-resistant microaerophilic Campylobacter gracilis-like clinical isolates. Int J Syst Bacteriol. 1996 Jan;46(1):252–258. doi: 10.1099/00207713-46-1-252. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES